首页> 外文学位 >Humanizing the jaa-f11 mouse monoclonal antibody.
【24h】

Humanizing the jaa-f11 mouse monoclonal antibody.

机译:人源化jaa-f11小鼠单克隆抗体。

获取原文
获取原文并翻译 | 示例

摘要

Thomsen-Friedenreich antigen (TF-Ag) is a carbohydrate antigen that is hidden on normal cells but present on the surface of many types of tumor cells including colon, breast, bladder, prostate, liver, ovary and stomach. Our laboratory has developed JAA-F11, a mouse monoclonal antibody that is highly specific for TF-Ag, which blocks the early stage of metastasis and improves survival in a mouse model. One drawback of mouse monoclonal antibodies is that they trigger the production of human anti-mouse antibody (HAMA) responses in patients which prevent their effective use. For this reason, humanization of the mouse JAA-F11 antibody is required. Our hypothesis was that the humanization of JAA-F11 can generate an antibody with the same or improved biological and chemical specificity as compared to the original mouse JAA-F11 mAb. To address this hypothesis, the first specific aim was to confirm the variable heavy and light regions of JAA-F11 mAb sequences and the second specific aim was to humanize the JAA-F11 antibody. The variable regions of heavy and light chain of JAA-F11 were first cloned and their sequences confirmed. The humanization of JAA-F11 was carried out by the complementary-determining regions (CDRs) grafting approach. Six variants which contained three variable heavy region constructs and three variable light region constructs were synthesized and further grafted respectively onto 6307 pAH human heavy and 6714 pAN light chain constant regions to form the complete antibody gene. The humanized heavy and light chains were co-transfected into CHO-K1 cells through electroporation to express the complete humanized antibody. Culture supernatant from the transfection was positive in ELISA showing that a humanized JAA-F11 antibody was successfully generated.
机译:Thomsen-Friedenreich抗原(TF-Ag)是一种碳水化合物抗原,隐藏在正常细胞上,但存在于许多类型肿瘤细胞的表面,包括结肠,乳腺癌,膀胱癌,前列腺癌,肝癌,卵巢癌和胃癌。我们的实验室已经开发出JAA-F11,这是一种对TF-Ag具有高度特异性的小鼠单克隆抗体,可阻断转移的早期阶段并提高小鼠模型的存活率。小鼠单克隆抗体的一个缺点是,它们会在患者体内触发人抗小鼠抗体(HAMA)反应的产生,从而阻止其有效使用。因此,需要小鼠JAA-F11抗体的人源化。我们的假设是,与原始小鼠JAA-F11 mAb相比,JAA-F11的人源化可以产生具有相同或改善的生物学和化学特异性的抗体。为了解决这个假设,第一个特定目标是确认JAA-F11 mAb序列的可变重链区和轻链区,第二个特定目标是使JAA-F11抗体人源化。首先克隆JAA-F11的重链和轻链的可变区,并确认其序列。 JAA-F11的人源化是通过互补决定区(CDR)移植方法进行的。合成了包含三个可变重区构建体和三个可变轻区构建体的六个变体,并分别进一步嫁接到6307pAH人重链和6714pAN轻链恒定区上,以形成完整的抗体基因。通过电穿孔将人源化的重链和轻链共转染到CHO-K1细胞中,以表达完整的人源化抗体。转染的培养上清液在ELISA中呈阳性,表明成功生成了人源化JAA-F11抗体。

著录项

  • 作者

    Eng, Jing Ying.;

  • 作者单位

    State University of New York at Buffalo.;

  • 授予单位 State University of New York at Buffalo.;
  • 学科 Health Sciences Immunology.;Health Sciences Oncology.;Biology Molecular.
  • 学位 M.S.
  • 年度 2014
  • 页码 175 p.
  • 总页数 175
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号